Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 453
- Registration Number
- NCT00776984
- Locations
- 🇺🇸
205.417.01062 Boehringer Ingelheim Investigational Site, Albany, New York, United States
🇺🇸205.417.01055 Boehringer Ingelheim Investigational Site, Rockville Centre, New York, United States
🇺🇸205.417.01061 Boehringer Ingelheim Investigational Site, Fountain Valley, California, United States
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: BI 201335 NA 120mg QD / LIDrug: PegIFN/RBVDrug: BI 201335 NA 240 mg QDDrug: BI 201335 NA 240 mg QD / LIDrug: BI 201335 NA 240 mg BIDDrug: Placebo
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 719
- Registration Number
- NCT00774397
- Locations
- 🇦🇹
1220.5.4302 Boehringer Ingelheim Investigational Site, Wien, Austria
🇺🇸1220.5.0008 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇺🇸1220.5.0001 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 459
- Registration Number
- NCT00772538
- Locations
- 🇺🇸
205.416.01014 Boehringer Ingelheim Investigational Site, Wheaton, Maryland, United States
🇩🇪205.416.49003 Boehringer Ingelheim Investigational Site, Gelnhausen, Germany
🇺🇸205.416.01008 Boehringer Ingelheim Investigational Site, San Diego, California, United States
Phase I Study of BI 831266 in Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- Drug: Arm ADrug: Arm B
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT00756223
- Locations
- 🇦🇹
1257.1.4303 Boehringer Ingelheim Investigational Site, Linz, Austria
🇦🇹1257.1.4301 Boehringer Ingelheim Investigational Site, Wien, Austria
🇦🇹1257.1.4302 Boehringer Ingelheim Investigational Site, Salzburg, Austria
Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1588
- Registration Number
- NCT00752388
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 2, Wuppertal, Germany
🇩🇪Boehringer Ingelheim Investigational Site 13, Berlin, Germany
🇩🇪Boehringer Ingelheim Investigational Site 14, Berlin, Germany
BI 44370 TA in Acute Migraine Attack
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 416
- Registration Number
- NCT00751803
- Locations
- 🇫🇷
1246.4.3301A Boehringer Ingelheim Investigational Site, Nice Cedex 1, France
🇫🇷1246.4.3305B Boehringer Ingelheim Investigational Site, Paris, France
🇧🇪1246.4.32004 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
- Conditions
- Neoplasms
- Interventions
- Drug: BIBW 2992 (Afatinib)
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT00748709
- Locations
- 🇺🇸
1200.26.12 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
🇺🇸1200.26.11 Boehringer Ingelheim Investigational Site, Denver, Colorado, United States
🇺🇸1200.26.2 Boehringer Ingelheim Investigational Site, New York, New York, United States
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 495
- Registration Number
- NCT00749190
- Locations
- 🇷🇴
1245.10.40002 Boehringer Ingelheim Investigational Site, Bucharest, Romania
🇷🇴1245.10.40004 Boehringer Ingelheim Investigational Site, Galati, Romania
🇺🇦1245.10.38001 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
- Conditions
- Migraine Disorders
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT00743015
- Locations
- 🇧🇪
1246.21.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇩🇪1246.21.49001 Boehringer Ingelheim Investigational Site, Berlin, Germany
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 227
- Registration Number
- NCT00740051
- Locations
- 🇺🇸
1218.50.10011 Boehringer Ingelheim Investigational Site, Peoria, Arizona, United States
🇺🇸1218.50.10002 Boehringer Ingelheim Investigational Site, Eugene, Oregon, United States
🇵🇭1218.50.63007 Boehringer Ingelheim Investigational Site, Pasay, Philippines